| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 132 | 2024 | 6945 | 4.060 |
Why?
|
| HIV Infections | 139 | 2024 | 17531 | 2.430 |
Why?
|
| CD4-Positive T-Lymphocytes | 43 | 2023 | 4405 | 1.510 |
Why?
|
| T-Lymphocytes, Cytotoxic | 38 | 2010 | 1800 | 1.310 |
Why?
|
| Viremia | 25 | 2014 | 727 | 1.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 52 | 2020 | 4641 | 1.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 15 | 2017 | 975 | 1.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 18 | 2014 | 1899 | 1.000 |
Why?
|
| Virus Replication | 29 | 2020 | 2450 | 0.960 |
Why?
|
| RNA, Viral | 27 | 2022 | 2866 | 0.870 |
Why?
|
| Viral Load | 44 | 2023 | 3385 | 0.850 |
Why?
|
| Epitopes, T-Lymphocyte | 23 | 2021 | 825 | 0.770 |
Why?
|
| Reproductive Health Services | 1 | 2022 | 90 | 0.740 |
Why?
|
| Virus Latency | 9 | 2023 | 359 | 0.740 |
Why?
|
| Anti-HIV Agents | 26 | 2015 | 4558 | 0.720 |
Why?
|
| Acquired Immunodeficiency Syndrome | 16 | 2007 | 2204 | 0.710 |
Why?
|
| Pregnancy in Adolescence | 1 | 2022 | 164 | 0.710 |
Why?
|
| HIV Antibodies | 12 | 2024 | 1337 | 0.680 |
Why?
|
| HIV Envelope Protein gp120 | 11 | 2024 | 923 | 0.670 |
Why?
|
| HIV Core Protein p24 | 16 | 2013 | 245 | 0.650 |
Why?
|
| Gene Products, gag | 13 | 2008 | 317 | 0.620 |
Why?
|
| HIV Long-Term Survivors | 9 | 2014 | 140 | 0.620 |
Why?
|
| Infectious Mononucleosis | 4 | 2010 | 133 | 0.620 |
Why?
|
| AIDS Vaccines | 6 | 2024 | 898 | 0.600 |
Why?
|
| Anaplasmosis | 2 | 2020 | 37 | 0.590 |
Why?
|
| Taq Polymerase | 1 | 2017 | 20 | 0.580 |
Why?
|
| HIV | 13 | 2011 | 1587 | 0.560 |
Why?
|
| HLA-B Antigens | 9 | 2013 | 329 | 0.530 |
Why?
|
| CD4 Lymphocyte Count | 23 | 2015 | 2586 | 0.520 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2020 | 335 | 0.500 |
Why?
|
| Proviruses | 5 | 2023 | 319 | 0.440 |
Why?
|
| Immunodominant Epitopes | 12 | 2014 | 244 | 0.440 |
Why?
|
| Borrelia Infections | 1 | 2013 | 17 | 0.440 |
Why?
|
| Acute Disease | 25 | 2014 | 7236 | 0.420 |
Why?
|
| Genome, Viral | 6 | 2020 | 674 | 0.410 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2013 | 379 | 0.380 |
Why?
|
| Interferon-gamma | 21 | 2015 | 3158 | 0.370 |
Why?
|
| Hepacivirus | 2 | 2017 | 1343 | 0.370 |
Why?
|
| Gloves, Surgical | 1 | 2011 | 24 | 0.370 |
Why?
|
| Encephalitis, Tick-Borne | 2 | 2024 | 45 | 0.370 |
Why?
|
| Encephalitis Viruses, Tick-Borne | 2 | 2024 | 48 | 0.370 |
Why?
|
| Splenic Infarction | 1 | 2010 | 12 | 0.360 |
Why?
|
| Vaccines, DNA | 2 | 2010 | 279 | 0.360 |
Why?
|
| Phlebotomy | 1 | 2011 | 138 | 0.340 |
Why?
|
| Epitope Mapping | 5 | 2005 | 300 | 0.340 |
Why?
|
| Professional Practice | 1 | 2012 | 314 | 0.340 |
Why?
|
| Gene Products, nef | 5 | 2006 | 101 | 0.330 |
Why?
|
| Humans | 219 | 2024 | 765926 | 0.320 |
Why?
|
| Meningitis, Aseptic | 1 | 2009 | 59 | 0.310 |
Why?
|
| Polymerase Chain Reaction | 8 | 2021 | 6058 | 0.310 |
Why?
|
| Case Management | 1 | 2010 | 276 | 0.310 |
Why?
|
| Models, Immunological | 2 | 2008 | 517 | 0.300 |
Why?
|
| Blood | 1 | 2011 | 597 | 0.300 |
Why?
|
| HIV Antigens | 10 | 2024 | 328 | 0.300 |
Why?
|
| Molecular Sequence Data | 35 | 2014 | 17596 | 0.300 |
Why?
|
| Cytotoxicity, Immunologic | 11 | 2014 | 1346 | 0.280 |
Why?
|
| Epitopes | 18 | 2024 | 2523 | 0.280 |
Why?
|
| Interferon Type I | 2 | 2024 | 567 | 0.280 |
Why?
|
| Bacteriological Techniques | 3 | 2014 | 276 | 0.280 |
Why?
|
| Dendritic Cells | 7 | 2020 | 2745 | 0.270 |
Why?
|
| Amino Acid Sequence | 31 | 2014 | 13398 | 0.270 |
Why?
|
| Cytomegalovirus Infections | 5 | 2014 | 837 | 0.270 |
Why?
|
| Th1 Cells | 4 | 2017 | 1040 | 0.260 |
Why?
|
| Genotype | 5 | 2022 | 13026 | 0.260 |
Why?
|
| Metagenomics | 2 | 2021 | 473 | 0.260 |
Why?
|
| Killer Cells, Natural | 7 | 2020 | 2206 | 0.250 |
Why?
|
| Antiviral Agents | 4 | 2023 | 3053 | 0.250 |
Why?
|
| HIV Seropositivity | 7 | 2024 | 961 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2014 | 4342 | 0.250 |
Why?
|
| Ross River virus | 1 | 2024 | 6 | 0.240 |
Why?
|
| Phylogeny | 6 | 2022 | 2837 | 0.240 |
Why?
|
| Interleukin-10 | 1 | 2010 | 1181 | 0.240 |
Why?
|
| Alphavirus Infections | 1 | 2024 | 20 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 9239 | 0.230 |
Why?
|
| Receptors, CCR5 | 7 | 2006 | 491 | 0.230 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2014 | 615 | 0.230 |
Why?
|
| Laboratories | 2 | 2021 | 463 | 0.230 |
Why?
|
| Disease Transmission, Infectious | 2 | 2013 | 560 | 0.220 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 6 | 2014 | 149 | 0.220 |
Why?
|
| Guided Tissue Regeneration, Periodontal | 3 | 1994 | 157 | 0.210 |
Why?
|
| Antigen Presentation | 6 | 2011 | 1250 | 0.210 |
Why?
|
| Sexual Behavior | 2 | 2022 | 2192 | 0.210 |
Why?
|
| Anti-Retroviral Agents | 6 | 2023 | 1786 | 0.210 |
Why?
|
| Virus Diseases | 3 | 2009 | 718 | 0.210 |
Why?
|
| Lymphocyte Activation | 12 | 2014 | 5500 | 0.200 |
Why?
|
| Vaccination | 3 | 2015 | 3430 | 0.200 |
Why?
|
| Immunity | 1 | 2008 | 1000 | 0.200 |
Why?
|
| Antigens, CD | 7 | 2011 | 4023 | 0.200 |
Why?
|
| Monocytes | 7 | 2020 | 2591 | 0.200 |
Why?
|
| HLA Antigens | 2 | 2006 | 1338 | 0.200 |
Why?
|
| Sex Education | 1 | 2022 | 92 | 0.190 |
Why?
|
| Antibodies, Viral | 5 | 2020 | 3213 | 0.190 |
Why?
|
| Laboratories, Hospital | 2 | 2021 | 192 | 0.190 |
Why?
|
| Hospitals, General | 2 | 2024 | 803 | 0.190 |
Why?
|
| Lymphocyte Subsets | 3 | 2014 | 313 | 0.190 |
Why?
|
| Diagnostic Test Approval | 1 | 2021 | 3 | 0.190 |
Why?
|
| Central Nervous System Viral Diseases | 1 | 2021 | 39 | 0.180 |
Why?
|
| Interleukin-6 | 2 | 2011 | 3225 | 0.180 |
Why?
|
| Histocompatibility Antigens Class I | 8 | 2014 | 1362 | 0.180 |
Why?
|
| Genetic Variation | 8 | 2016 | 6612 | 0.180 |
Why?
|
| HLA-A2 Antigen | 6 | 2005 | 207 | 0.180 |
Why?
|
| Flow Cytometry | 15 | 2014 | 5880 | 0.180 |
Why?
|
| Enterococcus faecium | 1 | 2021 | 101 | 0.180 |
Why?
|
| Contraception Behavior | 1 | 2022 | 185 | 0.170 |
Why?
|
| Macrolides | 1 | 2001 | 204 | 0.170 |
Why?
|
| Drug Administration Schedule | 7 | 2007 | 4851 | 0.170 |
Why?
|
| Transplantation | 1 | 2002 | 222 | 0.170 |
Why?
|
| DNA, Viral | 8 | 2022 | 2196 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2011 | 280 | 0.170 |
Why?
|
| Research Design | 4 | 2012 | 6204 | 0.170 |
Why?
|
| Anaplasma phagocytophilum | 1 | 2020 | 37 | 0.170 |
Why?
|
| Meningitis | 1 | 2021 | 218 | 0.170 |
Why?
|
| Patient Isolation | 1 | 2020 | 101 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 6 | 2020 | 1852 | 0.170 |
Why?
|
| Alveolar Ridge Augmentation | 2 | 1993 | 206 | 0.160 |
Why?
|
| Peptides | 6 | 2008 | 4331 | 0.160 |
Why?
|
| Adult | 61 | 2024 | 223088 | 0.160 |
Why?
|
| Antibodies, Neutralizing | 2 | 2024 | 2010 | 0.160 |
Why?
|
| Antibody Formation | 1 | 2004 | 1392 | 0.160 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2010 | 132 | 0.160 |
Why?
|
| Male | 71 | 2024 | 363815 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2017 | 1812 | 0.160 |
Why?
|
| Viral Proteins | 7 | 2004 | 1798 | 0.160 |
Why?
|
| Sexual Partners | 1 | 2004 | 804 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2021 | 340 | 0.160 |
Why?
|
| Medical Records | 1 | 2024 | 1408 | 0.160 |
Why?
|
| Chronic Disease | 19 | 2014 | 9351 | 0.160 |
Why?
|
| HLA-A Antigens | 6 | 2010 | 223 | 0.160 |
Why?
|
| Contraception | 1 | 2022 | 360 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 6 | 2014 | 1077 | 0.150 |
Why?
|
| Disease Susceptibility | 2 | 2013 | 1787 | 0.150 |
Why?
|
| Up-Regulation | 5 | 2017 | 4130 | 0.150 |
Why?
|
| Longitudinal Studies | 16 | 2014 | 14745 | 0.150 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2010 | 173 | 0.150 |
Why?
|
| Immune Evasion | 2 | 2012 | 376 | 0.150 |
Why?
|
| Receptors, HIV | 2 | 2017 | 159 | 0.150 |
Why?
|
| Autoantibodies | 2 | 2024 | 2114 | 0.150 |
Why?
|
| Genes, nef | 3 | 2008 | 52 | 0.150 |
Why?
|
| Giardiasis | 1 | 2018 | 28 | 0.150 |
Why?
|
| T-Lymphocytes | 7 | 2010 | 10256 | 0.150 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 7 | 2010 | 213 | 0.150 |
Why?
|
| HLA-C Antigens | 3 | 2014 | 146 | 0.150 |
Why?
|
| Disease Progression | 18 | 2014 | 13614 | 0.140 |
Why?
|
| Viruses | 1 | 2021 | 371 | 0.140 |
Why?
|
| Influenza, Human | 2 | 2022 | 1539 | 0.140 |
Why?
|
| Metagenome | 1 | 2021 | 464 | 0.140 |
Why?
|
| Encephalitis | 1 | 2021 | 440 | 0.140 |
Why?
|
| Receptors, CXCR4 | 2 | 2017 | 729 | 0.140 |
Why?
|
| Genes, pol | 3 | 2008 | 53 | 0.140 |
Why?
|
| Middle Aged | 52 | 2024 | 223016 | 0.140 |
Why?
|
| Viral Tropism | 1 | 2017 | 101 | 0.140 |
Why?
|
| beta-Defensins | 1 | 2017 | 58 | 0.140 |
Why?
|
| Lupus Nephritis | 1 | 2010 | 323 | 0.140 |
Why?
|
| Female | 65 | 2024 | 396141 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 2688 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2014 | 704 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2013 | 3801 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2013 | 3111 | 0.130 |
Why?
|
| Risk-Taking | 1 | 2022 | 1021 | 0.130 |
Why?
|
| Amino Acid Substitution | 7 | 2016 | 1740 | 0.130 |
Why?
|
| Models, Theoretical | 2 | 2016 | 3560 | 0.130 |
Why?
|
| Antibodies, Heterophile | 2 | 2010 | 128 | 0.130 |
Why?
|
| Limit of Detection | 1 | 2017 | 271 | 0.130 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2000 | 543 | 0.130 |
Why?
|
| Babesia microti | 1 | 2016 | 31 | 0.130 |
Why?
|
| Clone Cells | 4 | 2022 | 1670 | 0.130 |
Why?
|
| Genes, MHC Class I | 4 | 2010 | 236 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2012 | 4855 | 0.130 |
Why?
|
| Cytomegalovirus | 4 | 2014 | 753 | 0.130 |
Why?
|
| Superinfection | 2 | 2008 | 61 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 3661 | 0.120 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2013 | 169 | 0.120 |
Why?
|
| Genome, Protozoan | 1 | 2016 | 153 | 0.120 |
Why?
|
| Virus Integration | 2 | 2022 | 303 | 0.120 |
Why?
|
| Babesiosis | 1 | 2016 | 92 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2022 | 2570 | 0.120 |
Why?
|
| Cytokines | 7 | 2021 | 7417 | 0.120 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2015 | 39 | 0.120 |
Why?
|
| Fever | 4 | 2010 | 1607 | 0.120 |
Why?
|
| Staphylococcal Infections | 2 | 2014 | 1392 | 0.120 |
Why?
|
| Alleles | 12 | 2010 | 6891 | 0.110 |
Why?
|
| Telomerase | 2 | 2010 | 749 | 0.110 |
Why?
|
| Furcation Defects | 1 | 1994 | 37 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2022 | 1161 | 0.110 |
Why?
|
| Antigens, Differentiation | 2 | 2007 | 919 | 0.110 |
Why?
|
| Genes, gag | 3 | 2008 | 59 | 0.110 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2014 | 21 | 0.110 |
Why?
|
| Evolution, Molecular | 5 | 2016 | 1889 | 0.110 |
Why?
|
| Viral Regulatory and Accessory Proteins | 3 | 2002 | 151 | 0.110 |
Why?
|
| Base Sequence | 8 | 2022 | 12405 | 0.110 |
Why?
|
| Diagnosis, Differential | 7 | 2010 | 12973 | 0.110 |
Why?
|
| Cohort Studies | 20 | 2015 | 41680 | 0.110 |
Why?
|
| Disease Reservoirs | 1 | 2014 | 123 | 0.110 |
Why?
|
| Lymphocyte Count | 6 | 2007 | 791 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2024 | 1463 | 0.110 |
Why?
|
| Virus Attachment | 1 | 2013 | 55 | 0.110 |
Why?
|
| Influenza Vaccines | 2 | 2015 | 780 | 0.110 |
Why?
|
| Bacteria, Anaerobic | 1 | 1993 | 71 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 1172 | 0.100 |
Why?
|
| Neutralization Tests | 5 | 2011 | 735 | 0.100 |
Why?
|
| Human Immunodeficiency Virus Proteins | 3 | 2008 | 56 | 0.100 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 197 | 0.100 |
Why?
|
| Models, Biological | 3 | 2007 | 9443 | 0.100 |
Why?
|
| Mutation | 15 | 2010 | 30192 | 0.100 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 310 | 0.100 |
Why?
|
| Chemokines | 3 | 2021 | 956 | 0.100 |
Why?
|
| Myeloid Cells | 3 | 2020 | 838 | 0.100 |
Why?
|
| Cell Polarity | 1 | 2015 | 636 | 0.100 |
Why?
|
| Immunity, Cellular | 5 | 2011 | 1555 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2011 | 2814 | 0.100 |
Why?
|
| Antigens, Viral | 2 | 2008 | 995 | 0.100 |
Why?
|
| Respirovirus Infections | 1 | 2011 | 51 | 0.100 |
Why?
|
| HLA-A3 Antigen | 3 | 2006 | 34 | 0.090 |
Why?
|
| Cells, Cultured | 12 | 2020 | 18962 | 0.090 |
Why?
|
| Selection, Genetic | 4 | 2016 | 877 | 0.090 |
Why?
|
| Telomere-Binding Proteins | 1 | 2012 | 122 | 0.090 |
Why?
|
| Physiology | 1 | 1991 | 112 | 0.090 |
Why?
|
| Periodontitis | 2 | 1994 | 576 | 0.090 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2010 | 48 | 0.090 |
Why?
|
| HIV Integrase | 1 | 2012 | 121 | 0.090 |
Why?
|
| Early Diagnosis | 2 | 2013 | 1186 | 0.090 |
Why?
|
| Transcription, Genetic | 2 | 2022 | 7599 | 0.090 |
Why?
|
| Pneumonia | 1 | 2022 | 2158 | 0.090 |
Why?
|
| Esthetics, Dental | 1 | 1993 | 267 | 0.090 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 374 | 0.090 |
Why?
|
| Hospital Departments | 1 | 2011 | 134 | 0.090 |
Why?
|
| Nasal Mucosa | 1 | 2014 | 416 | 0.090 |
Why?
|
| Goiter | 1 | 2010 | 86 | 0.090 |
Why?
|
| HIV Protease Inhibitors | 3 | 2003 | 430 | 0.090 |
Why?
|
| Receptors, Interferon | 1 | 2010 | 114 | 0.090 |
Why?
|
| HLA-DR Antigens | 3 | 2012 | 608 | 0.090 |
Why?
|
| Heptanoic Acids | 1 | 2012 | 344 | 0.080 |
Why?
|
| Phenotype | 6 | 2023 | 16714 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 4 | 2021 | 7473 | 0.080 |
Why?
|
| Abdominal Pain | 2 | 2010 | 1069 | 0.080 |
Why?
|
| Aerospace Medicine | 1 | 2010 | 95 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 373 | 0.080 |
Why?
|
| Splenomegaly | 1 | 2010 | 191 | 0.080 |
Why?
|
| Pain Measurement | 3 | 2010 | 3558 | 0.080 |
Why?
|
| Histocompatibility Testing | 3 | 2007 | 726 | 0.080 |
Why?
|
| Peptide Fragments | 8 | 2005 | 5126 | 0.080 |
Why?
|
| Didanosine | 2 | 1999 | 151 | 0.080 |
Why?
|
| Receptors, KIR3DS1 | 1 | 2009 | 9 | 0.080 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2009 | 27 | 0.080 |
Why?
|
| Drug Therapy, Combination | 6 | 2003 | 6306 | 0.080 |
Why?
|
| Protein Binding | 3 | 2016 | 9296 | 0.080 |
Why?
|
| Th17 Cells | 1 | 2015 | 786 | 0.080 |
Why?
|
| Disinfection | 1 | 2011 | 207 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 702 | 0.080 |
Why?
|
| Macrophage Activation | 1 | 2011 | 552 | 0.080 |
Why?
|
| Lung | 2 | 2024 | 10046 | 0.080 |
Why?
|
| Toll-Like Receptors | 1 | 2012 | 582 | 0.080 |
Why?
|
| CD4-CD8 Ratio | 4 | 2009 | 114 | 0.080 |
Why?
|
| Hydroxyurea | 2 | 1999 | 284 | 0.080 |
Why?
|
| Alveolar Bone Loss | 1 | 1992 | 394 | 0.080 |
Why?
|
| Gene Products, vpr | 3 | 2005 | 33 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2014 | 2925 | 0.080 |
Why?
|
| Health Policy | 1 | 2021 | 2699 | 0.080 |
Why?
|
| AIDS Dementia Complex | 1 | 2009 | 154 | 0.070 |
Why?
|
| Macrophages | 3 | 2012 | 5772 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2011 | 549 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 614 | 0.070 |
Why?
|
| Cell Survival | 4 | 2023 | 5745 | 0.070 |
Why?
|
| Frontal Lobe | 2 | 2011 | 1408 | 0.070 |
Why?
|
| Radiography, Abdominal | 1 | 2010 | 543 | 0.070 |
Why?
|
| Colon, Sigmoid | 1 | 2007 | 124 | 0.070 |
Why?
|
| Immunity, Innate | 4 | 2020 | 3078 | 0.070 |
Why?
|
| Boston | 6 | 2020 | 9334 | 0.070 |
Why?
|
| Anemia | 2 | 2010 | 1514 | 0.070 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2024 | 381 | 0.070 |
Why?
|
| Probability | 1 | 2012 | 2474 | 0.070 |
Why?
|
| Adolescent | 11 | 2022 | 88811 | 0.070 |
Why?
|
| Virus Activation | 1 | 2008 | 322 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2010 | 1605 | 0.070 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2006 | 70 | 0.070 |
Why?
|
| Parasite Egg Count | 1 | 2006 | 29 | 0.070 |
Why?
|
| Exanthema | 2 | 2009 | 503 | 0.070 |
Why?
|
| B-Lymphocytes | 4 | 2020 | 4782 | 0.060 |
Why?
|
| Pyrroles | 1 | 2012 | 1119 | 0.060 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2005 | 89 | 0.060 |
Why?
|
| Observer Variation | 1 | 2012 | 2611 | 0.060 |
Why?
|
| Cerebral Palsy | 1 | 2010 | 481 | 0.060 |
Why?
|
| Interleukins | 1 | 2010 | 789 | 0.060 |
Why?
|
| Vomiting | 1 | 2009 | 646 | 0.060 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2005 | 38 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2007 | 606 | 0.060 |
Why?
|
| Cross Reactions | 2 | 2006 | 824 | 0.060 |
Why?
|
| Cell Proliferation | 6 | 2013 | 10426 | 0.060 |
Why?
|
| Polymorphism, Genetic | 4 | 2014 | 4249 | 0.060 |
Why?
|
| Species Specificity | 4 | 2014 | 2406 | 0.060 |
Why?
|
| Carcinoma, Papillary | 1 | 2010 | 786 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 746 | 0.060 |
Why?
|
| Drug Resistance, Viral | 3 | 2010 | 867 | 0.060 |
Why?
|
| Kidney | 1 | 2010 | 7073 | 0.060 |
Why?
|
| Cell Line | 11 | 2017 | 15540 | 0.060 |
Why?
|
| Neopterin | 1 | 2005 | 57 | 0.060 |
Why?
|
| Integrases | 1 | 2007 | 520 | 0.060 |
Why?
|
| Liver | 1 | 2010 | 7559 | 0.060 |
Why?
|
| Flavivirus | 1 | 2024 | 23 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 970 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 5 | 2015 | 4780 | 0.060 |
Why?
|
| Behavior Therapy | 1 | 2010 | 886 | 0.060 |
Why?
|
| Bodily Secretions | 1 | 2004 | 28 | 0.060 |
Why?
|
| Molecular Mimicry | 1 | 2005 | 210 | 0.060 |
Why?
|
| Animals | 14 | 2020 | 168735 | 0.060 |
Why?
|
| Thyroid Gland | 1 | 2010 | 1168 | 0.060 |
Why?
|
| beta 2-Microglobulin | 1 | 2005 | 330 | 0.060 |
Why?
|
| HIV Seroprevalence | 1 | 2004 | 89 | 0.060 |
Why?
|
| Case-Control Studies | 8 | 2021 | 22228 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2003 | 52 | 0.050 |
Why?
|
| Retrospective Studies | 8 | 2023 | 81537 | 0.050 |
Why?
|
| Immunologic Memory | 2 | 2023 | 1374 | 0.050 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2023 | 32 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2015 | 2184 | 0.050 |
Why?
|
| Interleukin-2 | 3 | 2008 | 1894 | 0.050 |
Why?
|
| Pregnancy | 3 | 2022 | 30230 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 9525 | 0.050 |
Why?
|
| Genitalia, Female | 1 | 2004 | 146 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 2010 | 2589 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 1600 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 3733 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2005 | 812 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2011 | 3678 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 4859 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 6491 | 0.050 |
Why?
|
| Amino Acids | 2 | 2024 | 1709 | 0.050 |
Why?
|
| Macaca | 1 | 2004 | 413 | 0.050 |
Why?
|
| Time Factors | 10 | 2019 | 40097 | 0.050 |
Why?
|
| Immunophenotyping | 4 | 2013 | 1865 | 0.050 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 14643 | 0.050 |
Why?
|
| Sulfates | 1 | 2003 | 375 | 0.050 |
Why?
|
| Stem Cells | 1 | 2015 | 3537 | 0.050 |
Why?
|
| Ionomycin | 1 | 2022 | 109 | 0.050 |
Why?
|
| HLA-B27 Antigen | 3 | 2008 | 66 | 0.050 |
Why?
|
| Aged | 15 | 2024 | 171163 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2002 | 1695 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2002 | 75 | 0.050 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 15401 | 0.050 |
Why?
|
| Brefeldin A | 1 | 2001 | 68 | 0.050 |
Why?
|
| Cyclophilins | 1 | 2001 | 47 | 0.050 |
Why?
|
| Egtazic Acid | 1 | 2001 | 165 | 0.050 |
Why?
|
| Inflammation | 1 | 2021 | 10843 | 0.050 |
Why?
|
| United States | 6 | 2022 | 72909 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2005 | 650 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 7871 | 0.050 |
Why?
|
| Viral Vaccines | 2 | 2012 | 596 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 3690 | 0.050 |
Why?
|
| Gene Products, rev | 1 | 2001 | 29 | 0.050 |
Why?
|
| Immunologic Factors | 2 | 2018 | 1590 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2021 | 1970 | 0.050 |
Why?
|
| Semen | 1 | 2004 | 351 | 0.050 |
Why?
|
| Pain | 2 | 2007 | 5077 | 0.050 |
Why?
|
| Headache | 1 | 2009 | 1261 | 0.050 |
Why?
|
| Gene Products, tat | 1 | 2001 | 111 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2022 | 822 | 0.040 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2010 | 73 | 0.040 |
Why?
|
| Perception | 1 | 2007 | 1204 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 2 | 2000 | 832 | 0.040 |
Why?
|
| Antigenic Variation | 3 | 2006 | 117 | 0.040 |
Why?
|
| Jaundice | 1 | 2010 | 94 | 0.040 |
Why?
|
| Immunity, Mucosal | 1 | 2004 | 498 | 0.040 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2010 | 141 | 0.040 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 2782 | 0.040 |
Why?
|
| Heterochromatin | 1 | 2023 | 294 | 0.040 |
Why?
|
| Influenza A virus | 1 | 2004 | 453 | 0.040 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2011 | 1529 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 136 | 0.040 |
Why?
|
| Analgesics, Opioid | 2 | 2007 | 3834 | 0.040 |
Why?
|
| Indinavir | 1 | 1999 | 73 | 0.040 |
Why?
|
| Drug Design | 1 | 2005 | 1039 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 2010 | 160 | 0.040 |
Why?
|
| Education, Medical | 1 | 1991 | 1744 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2007 | 1064 | 0.040 |
Why?
|
| Culicidae | 1 | 2020 | 111 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2022 | 665 | 0.040 |
Why?
|
| Biological Evolution | 2 | 2022 | 1075 | 0.040 |
Why?
|
| Plasma | 2 | 2014 | 583 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1999 | 109 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2002 | 15802 | 0.040 |
Why?
|
| Lentivirus | 1 | 2022 | 518 | 0.040 |
Why?
|
| Feces | 1 | 2006 | 1503 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2020 | 404 | 0.040 |
Why?
|
| Tyrosine | 1 | 2003 | 1427 | 0.040 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 3 | 2005 | 36 | 0.040 |
Why?
|
| Immunization | 1 | 2003 | 1218 | 0.040 |
Why?
|
| DNA Primers | 3 | 2011 | 2824 | 0.040 |
Why?
|
| Confusion | 1 | 2010 | 278 | 0.040 |
Why?
|
| HIV-2 | 1 | 1999 | 156 | 0.040 |
Why?
|
| Young Adult | 8 | 2018 | 59857 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 20133 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2024 | 1572 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2002 | 1133 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2002 | 1440 | 0.040 |
Why?
|
| Gallstones | 1 | 2010 | 285 | 0.040 |
Why?
|
| Colorado | 1 | 2018 | 167 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 216 | 0.040 |
Why?
|
| Myxococcales | 1 | 1977 | 15 | 0.040 |
Why?
|
| Algorithms | 2 | 2020 | 14064 | 0.040 |
Why?
|
| Myocardium | 1 | 2010 | 4764 | 0.040 |
Why?
|
| Nausea | 1 | 2010 | 678 | 0.040 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 1997 | 95 | 0.040 |
Why?
|
| Aspartic Acid | 2 | 2011 | 575 | 0.040 |
Why?
|
| Minnesota | 1 | 2018 | 339 | 0.040 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 1998 | 140 | 0.040 |
Why?
|
| Pruritus | 1 | 2010 | 376 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2010 | 2354 | 0.030 |
Why?
|
| Financing, Government | 1 | 2021 | 473 | 0.030 |
Why?
|
| Smoking | 1 | 1994 | 9082 | 0.030 |
Why?
|
| Mass Screening | 1 | 2013 | 5449 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3249 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2844 | 0.030 |
Why?
|
| Virus Cultivation | 2 | 2000 | 88 | 0.030 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 120 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2021 | 54807 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2019 | 437 | 0.030 |
Why?
|
| Germany | 2 | 2012 | 882 | 0.030 |
Why?
|
| Microfluidics | 1 | 2022 | 651 | 0.030 |
Why?
|
| Atovaquone | 1 | 2016 | 56 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2021 | 697 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2021 | 407 | 0.030 |
Why?
|
| Cytochromes b | 1 | 2016 | 35 | 0.030 |
Why?
|
| Logistic Models | 4 | 2018 | 13273 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2024 | 2760 | 0.030 |
Why?
|
| Government Regulation | 1 | 2021 | 525 | 0.030 |
Why?
|
| Central Nervous System Diseases | 1 | 2010 | 519 | 0.030 |
Why?
|
| Haplotypes | 2 | 2014 | 2726 | 0.030 |
Why?
|
| Homozygote | 1 | 2001 | 1774 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1999 | 618 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2022 | 1504 | 0.030 |
Why?
|
| Acetates | 1 | 1977 | 314 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1657 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2012 | 12803 | 0.030 |
Why?
|
| Simian immunodeficiency virus | 1 | 2000 | 812 | 0.030 |
Why?
|
| Zoonoses | 1 | 2016 | 180 | 0.030 |
Why?
|
| Georgia | 1 | 2015 | 186 | 0.030 |
Why?
|
| Receptors, KIR2DL2 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2014 | 13 | 0.030 |
Why?
|
| Receptors, KIR2DL3 | 1 | 2014 | 15 | 0.030 |
Why?
|
| Azithromycin | 1 | 2016 | 202 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 1037 | 0.030 |
Why?
|
| Models, Molecular | 3 | 2011 | 5377 | 0.030 |
Why?
|
| Treatment Outcome | 8 | 2014 | 65194 | 0.030 |
Why?
|
| Abdomen | 1 | 2010 | 1135 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 12529 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 663 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2012 | 12417 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 20690 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2014 | 126 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2021 | 1065 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 241 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2016 | 367 | 0.030 |
Why?
|
| Glycine | 1 | 1977 | 671 | 0.030 |
Why?
|
| Tooth Eruption | 1 | 1993 | 29 | 0.030 |
Why?
|
| Epithelial Attachment | 1 | 1993 | 46 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 856 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2000 | 2341 | 0.030 |
Why?
|
| Patient Selection | 2 | 2004 | 4248 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 3270 | 0.030 |
Why?
|
| Brain | 2 | 2012 | 27179 | 0.030 |
Why?
|
| Gingival Diseases | 1 | 1993 | 37 | 0.030 |
Why?
|
| Consensus Sequence | 2 | 2005 | 363 | 0.030 |
Why?
|
| Body Composition | 1 | 2003 | 2441 | 0.030 |
Why?
|
| Antibodies | 1 | 2001 | 2415 | 0.030 |
Why?
|
| Wolinella | 1 | 1993 | 9 | 0.030 |
Why?
|
| Physician Executives | 1 | 2014 | 140 | 0.030 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2014 | 238 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 667 | 0.030 |
Why?
|
| Eikenella corrodens | 1 | 1993 | 17 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2018 | 42510 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2010 | 5987 | 0.030 |
Why?
|
| Work | 1 | 2014 | 195 | 0.030 |
Why?
|
| Protein Conformation | 2 | 2011 | 3945 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2018 | 9656 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 2 | 2005 | 423 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2716 | 0.030 |
Why?
|
| Advance Directives | 1 | 1995 | 249 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2007 | 2430 | 0.030 |
Why?
|
| Gingivoplasty | 1 | 1993 | 37 | 0.030 |
Why?
|
| Periodontal Index | 1 | 1993 | 149 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2008 | 1150 | 0.030 |
Why?
|
| Bystander Effect | 1 | 2013 | 89 | 0.030 |
Why?
|
| Periodontal Pocket | 1 | 1993 | 174 | 0.030 |
Why?
|
| Bacteroides | 1 | 1993 | 165 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 1993 | 326 | 0.020 |
Why?
|
| HLA-B7 Antigen | 2 | 2002 | 48 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1673 | 0.020 |
Why?
|
| Porphyromonas gingivalis | 1 | 1993 | 165 | 0.020 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2011 | 25 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2002 | 18292 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2002 | 1596 | 0.020 |
Why?
|
| Genomic Structural Variation | 1 | 2012 | 81 | 0.020 |
Why?
|
| Tissue Expansion | 1 | 1993 | 163 | 0.020 |
Why?
|
| Massachusetts | 1 | 2024 | 8882 | 0.020 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2012 | 98 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2023 | 3447 | 0.020 |
Why?
|
| Decision Making | 1 | 2005 | 3955 | 0.020 |
Why?
|
| Recurrence | 2 | 2016 | 8492 | 0.020 |
Why?
|
| Tooth Root | 1 | 1992 | 161 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 1761 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 2005 | 2172 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2003 | 3314 | 0.020 |
Why?
|
| Reference Standards | 1 | 2014 | 1011 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2011 | 68 | 0.020 |
Why?
|
| Risk Factors | 3 | 2018 | 74850 | 0.020 |
Why?
|
| Granzymes | 1 | 2012 | 278 | 0.020 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2010 | 100 | 0.020 |
Why?
|
| Inositol | 1 | 2011 | 215 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1621 | 0.020 |
Why?
|
| Interferon-beta | 1 | 2012 | 346 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2015 | 1074 | 0.020 |
Why?
|
| Binding Sites | 3 | 2004 | 5999 | 0.020 |
Why?
|
| Chromatin | 1 | 2022 | 2979 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2018 | 2353 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 11508 | 0.020 |
Why?
|
| Osteopontin | 1 | 2011 | 304 | 0.020 |
Why?
|
| Neurons | 1 | 2009 | 9527 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2011 | 12768 | 0.020 |
Why?
|
| Cardiac Tamponade | 1 | 2010 | 175 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 486 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 472 | 0.020 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2009 | 9 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 10727 | 0.020 |
Why?
|
| False Positive Reactions | 2 | 2002 | 956 | 0.020 |
Why?
|
| Analgesics | 2 | 2007 | 1057 | 0.020 |
Why?
|
| Choline | 1 | 2011 | 511 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2011 | 602 | 0.020 |
Why?
|
| Forecasting | 1 | 1998 | 2936 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2011 | 581 | 0.020 |
Why?
|
| Sex Factors | 1 | 2003 | 10611 | 0.020 |
Why?
|
| Cell Count | 1 | 2013 | 1823 | 0.020 |
Why?
|
| Kinetics | 2 | 2007 | 6273 | 0.020 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2010 | 262 | 0.020 |
Why?
|
| L-Selectin | 1 | 2009 | 212 | 0.020 |
Why?
|
| Genes, env | 1 | 2008 | 96 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 1590 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2011 | 1154 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2011 | 419 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 3816 | 0.020 |
Why?
|
| Radiography | 2 | 2010 | 6941 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 2012 | 3690 | 0.020 |
Why?
|
| Proteins | 1 | 2003 | 5994 | 0.020 |
Why?
|
| Apoptosis | 2 | 2018 | 9505 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2012 | 1336 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 1677 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2011 | 559 | 0.020 |
Why?
|
| Treatment Failure | 1 | 1994 | 2653 | 0.020 |
Why?
|
| Dental Implantation, Endosseous | 1 | 1992 | 520 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 1995 | 1404 | 0.020 |
Why?
|
| Staining and Labeling | 2 | 2002 | 1072 | 0.020 |
Why?
|
| Thyroid Diseases | 1 | 2010 | 385 | 0.020 |
Why?
|
| Biological Transport | 1 | 1991 | 2081 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2000 | 8724 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2010 | 1029 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3886 | 0.020 |
Why?
|
| Gadolinium | 1 | 2012 | 966 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 36547 | 0.020 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2006 | 41 | 0.020 |
Why?
|
| Homeostasis | 2 | 2003 | 3338 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 2717 | 0.020 |
Why?
|
| Disulfides | 1 | 2009 | 461 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4563 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2011 | 1692 | 0.020 |
Why?
|
| Dientamoeba | 1 | 2006 | 2 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 2120 | 0.020 |
Why?
|
| Child | 8 | 2018 | 80568 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 97 | 0.020 |
Why?
|
| Giardia lamblia | 1 | 2006 | 23 | 0.020 |
Why?
|
| Cryptosporidium parvum | 1 | 2006 | 35 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 2007 | 276 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2011 | 865 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 1835 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2002 | 4746 | 0.020 |
Why?
|
| Dissent and Disputes | 1 | 2007 | 150 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2010 | 665 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 3271 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 7423 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 4520 | 0.020 |
Why?
|
| Cross-Sectional Studies | 4 | 2011 | 26282 | 0.020 |
Why?
|
| Shock, Cardiogenic | 1 | 2010 | 705 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2006 | 561 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 2010 | 912 | 0.010 |
Why?
|
| Portal Vein | 1 | 2007 | 437 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 1258 | 0.010 |
Why?
|
| Organ Transplantation | 1 | 2014 | 1172 | 0.010 |
Why?
|
| Viral Structural Proteins | 1 | 2004 | 93 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2001 | 1353 | 0.010 |
Why?
|
| Sequence Analysis, RNA | 1 | 2012 | 2036 | 0.010 |
Why?
|
| Teaching | 1 | 1991 | 1170 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 1721 | 0.010 |
Why?
|
| Chest Pain | 1 | 2010 | 1102 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2008 | 1525 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3796 | 0.010 |
Why?
|
| Parasites | 1 | 2006 | 159 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2009 | 1181 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 1995 | 2418 | 0.010 |
Why?
|
| Antigens | 1 | 2009 | 1437 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2004 | 654 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2005 | 1061 | 0.010 |
Why?
|
| HLA-DR1 Antigen | 1 | 2002 | 11 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 2423 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 1527 | 0.010 |
Why?
|
| Spodoptera | 1 | 2002 | 140 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 1893 | 0.010 |
Why?
|
| Hybridomas | 1 | 2003 | 442 | 0.010 |
Why?
|
| Telomere | 1 | 2008 | 941 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2004 | 482 | 0.010 |
Why?
|
| HLA-A1 Antigen | 1 | 2001 | 9 | 0.010 |
Why?
|
| Gene Products, vif | 1 | 2001 | 31 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2004 | 731 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2005 | 1159 | 0.010 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 51 | 0.010 |
Why?
|
| Lamivudine | 1 | 2003 | 368 | 0.010 |
Why?
|
| Cell Communication | 1 | 2009 | 1660 | 0.010 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 26 | 0.010 |
Why?
|
| Ligands | 1 | 2008 | 3272 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6503 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 1498 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 880 | 0.010 |
Why?
|
| Receptors, KIR | 1 | 2001 | 114 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 119 | 0.010 |
Why?
|
| Diarrhea | 1 | 2007 | 1315 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8721 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2000 | 317 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1991 | 2894 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 59496 | 0.010 |
Why?
|
| Hospitalization | 1 | 2020 | 10810 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2007 | 1127 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 4555 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2004 | 1750 | 0.010 |
Why?
|
| Lysosomes | 1 | 2005 | 932 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2003 | 1180 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 1938 | 0.010 |
Why?
|
| Reference Values | 1 | 2007 | 4909 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2011 | 4498 | 0.010 |
Why?
|
| Oxygen | 1 | 2011 | 4246 | 0.010 |
Why?
|
| HIV Protease | 1 | 1999 | 99 | 0.010 |
Why?
|
| Colitis | 1 | 2007 | 1239 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 2743 | 0.010 |
Why?
|
| Stents | 1 | 2010 | 3191 | 0.010 |
Why?
|
| Contrast Media | 1 | 2012 | 5330 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 8522 | 0.010 |
Why?
|
| Prognosis | 2 | 2012 | 29890 | 0.010 |
Why?
|
| Infant | 2 | 2018 | 36426 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 1999 | 214 | 0.010 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2000 | 306 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2003 | 676 | 0.010 |
Why?
|
| Curriculum | 1 | 1991 | 3784 | 0.010 |
Why?
|
| Half-Life | 1 | 1999 | 645 | 0.010 |
Why?
|
| Uridine Diphosphate N-Acetylgalactosamine | 1 | 1977 | 9 | 0.010 |
Why?
|
| Echocardiography | 1 | 2010 | 5040 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1319 | 0.010 |
Why?
|
| Uridine Diphosphate N-Acetylglucosamine | 1 | 1977 | 18 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2007 | 11639 | 0.010 |
Why?
|
| Bacitracin | 1 | 1977 | 24 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2003 | 3049 | 0.010 |
Why?
|
| Penicillin G | 1 | 1977 | 40 | 0.010 |
Why?
|
| Chloramphenicol | 1 | 1977 | 67 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 26380 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 5738 | 0.010 |
Why?
|
| Heart | 1 | 2010 | 4419 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2010 | 6409 | 0.010 |
Why?
|
| Adiponectin | 1 | 2003 | 1120 | 0.010 |
Why?
|
| Spores, Bacterial | 1 | 1977 | 114 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2003 | 1707 | 0.010 |
Why?
|
| Cycloserine | 1 | 1977 | 118 | 0.010 |
Why?
|
| Glycerol | 1 | 1977 | 274 | 0.010 |
Why?
|
| Valine | 1 | 1977 | 410 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2001 | 1415 | 0.010 |
Why?
|
| Control Groups | 1 | 1995 | 106 | 0.010 |
Why?
|
| South Africa | 1 | 2000 | 1868 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1977 | 576 | 0.010 |
Why?
|
| Cell Wall | 1 | 1977 | 419 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 3623 | 0.010 |
Why?
|
| Gingivectomy | 1 | 1993 | 14 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 4535 | 0.010 |
Why?
|
| Israel | 1 | 1995 | 729 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 11895 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1999 | 5019 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 4466 | 0.010 |
Why?
|
| Indicator Dilution Techniques | 1 | 1991 | 43 | 0.010 |
Why?
|
| Mice | 1 | 1998 | 81782 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 16039 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 8616 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 1995 | 619 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2007 | 4736 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 23597 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2002 | 4210 | 0.010 |
Why?
|
| Insulin | 1 | 2003 | 6603 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 2470 | 0.000 |
Why?
|
| Data Collection | 1 | 1995 | 3318 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2003 | 13042 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 39228 | 0.000 |
Why?
|
| Bacterial Proteins | 1 | 1977 | 3829 | 0.000 |
Why?
|
| Aging | 1 | 2000 | 8725 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1995 | 8037 | 0.000 |
Why?
|